358 related articles for article (PubMed ID: 26088137)
1. Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
Koenig P; Lee CV; Sanowar S; Wu P; Stinson J; Harris SF; Fuh G
J Biol Chem; 2015 Sep; 290(36):21773-86. PubMed ID: 26088137
[TBL] [Abstract][Full Text] [Related]
2. Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.
Koenig P; Sanowar S; Lee CV; Fuh G
MAbs; 2017; 9(6):959-967. PubMed ID: 28585908
[TBL] [Abstract][Full Text] [Related]
3. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity.
Bostrom J; Haber L; Koenig P; Kelley RF; Fuh G
PLoS One; 2011 Apr; 6(4):e17887. PubMed ID: 21526167
[TBL] [Abstract][Full Text] [Related]
4. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
5. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
Tesar D; Luoma J; Wyatt EA; Shi C; Shatz W; Hass PE; Mathieu M; Yi L; Corn JE; Maass KF; Wang K; Dion MZ; Andersen N; Loyet KM; van Lookeren Campagne M; Rajagopal K; Dickmann L; Scheer JM; Kelley RF
MAbs; 2017; 9(8):1297-1305. PubMed ID: 28854082
[TBL] [Abstract][Full Text] [Related]
6. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
7. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
[TBL] [Abstract][Full Text] [Related]
8. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.
Tiller KE; Li L; Kumar S; Julian MC; Garde S; Tessier PM
J Biol Chem; 2017 Oct; 292(40):16638-16652. PubMed ID: 28778924
[TBL] [Abstract][Full Text] [Related]
9. Improved binding activity of antibodies against major histocompatibility complex class I chain-related gene A by phage display technology for cancer-targeted therapy.
Phumyen A; Jumnainsong A; Leelayuwat C
J Biomed Biotechnol; 2012; 2012():597647. PubMed ID: 23226940
[TBL] [Abstract][Full Text] [Related]
10. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.
Lee CV; Koenig P; Fuh G
MAbs; 2014; 6(3):622-7. PubMed ID: 24618680
[TBL] [Abstract][Full Text] [Related]
11. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
12. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
[TBL] [Abstract][Full Text] [Related]
13. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ziemssen F; Heiduschka P; Schraermeyer U;
Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
[No Abstract] [Full Text] [Related]
14. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Khan M; Aziz AA; Shafi NA; Abbas T; Khanani AM
Cells; 2020 Aug; 9(8):. PubMed ID: 32785136
[TBL] [Abstract][Full Text] [Related]
15. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM
Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.
Finlay WJJ; Coleman JE; Edwards JS; Johnson KS
MAbs; 2019 Jan; 11(1):26-44. PubMed ID: 30541416
[TBL] [Abstract][Full Text] [Related]
17. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.
Lee CV; Liang WC; Dennis MS; Eigenbrot C; Sidhu SS; Fuh G
J Mol Biol; 2004 Jul; 340(5):1073-93. PubMed ID: 15236968
[TBL] [Abstract][Full Text] [Related]
18. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
[TBL] [Abstract][Full Text] [Related]
19. [Avastin is not the same as Lucentis, and Lucentis is not the same as Avastin].
Asensio-Sánchez VM
Arch Soc Esp Oftalmol; 2009 Sep; 84(9):427. PubMed ID: 19809922
[No Abstract] [Full Text] [Related]
20. An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries.
Petersen BM; Kirby MB; Chrispens KM; Irvin OM; Strawn IK; Haas CM; Walker AM; Baumer ZT; Ulmer SA; Ayala E; Rhodes ER; Guthmiller JJ; Steiner PJ; Whitehead TA
Nat Commun; 2024 May; 15(1):3974. PubMed ID: 38730230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
